Progestogen (medication): Difference between revisions

Content deleted Content added
remove url when have doi
 
(One intermediate revision by one other user not shown)
Line 4:
{{Infobox drug class
| Image = Progesterone.svg
| ImageClass = skin-invert-image
| Caption = [[Progesterone (medication)|Progesterone]], the natural progestogen in the body and one of the most widely used progestogen medications
| Width = 225px
Line 337 ⟶ 338:
 
====Antigonadotropic effects====
Progestogens, similarly to the androgens and estrogens through their own respective [[receptor (biochemistry)|receptorreceptors]]s, inhibit the secretion of the [[gonadotropin]]s [[follicle-stimulating hormone]] (FSH) and [[luteinizing hormone]] (LH) via activation of the PR in the [[pituitary gland]]. This effect is a form of [[negative feedback]] on the [[hypothalamic–pituitary–gonadal axis]] (HPG axis) and takes advantage of the mechanism that the body uses to prevent [[sex hormone]] levels from becoming too high.<ref name="pmid10997774">{{cite journal |vauthors=de Lignières B, Silberstein S | title = Pharmacodynamics of oestrogens and progestogens | journal = Cephalalgia: An International Journal of Headache | volume = 20 | issue = 3 | pages = 200–7 |date=April 2000 | pmid = 10997774 | doi = 10.1046/j.1468-2982.2000.00042.x| s2cid = 40392817 | doi-access = free }}</ref><ref name="pmid15752663">{{cite journal |vauthors=Chassard D, Schatz B | title = [The antigonadrotropic activity of chlormadinone acetate in reproductive women] | language = fr | journal = Gynécologie, Obstétrique & Fertilité | volume = 33 | issue = 1–2 | pages = 29–34 | year = 2005 | pmid = 15752663 | doi = 10.1016/j.gyobfe.2004.12.002 }}</ref><ref name="pmid12641635">{{cite journal |vauthors=Brady BM, Anderson RA, Kinniburgh D, Baird DT | title = Demonstration of progesterone receptor-mediated gonadotrophin suppression in the human male | journal = Clinical Endocrinology | volume = 58 | issue = 4 | pages = 506–12 |date=April 2003 | pmid = 12641635 | doi = 10.1046/j.1365-2265.2003.01751.x| s2cid = 12567639 | doi-access = free }}</ref> Accordingly, progestogens, both endogenous and exogenous (i.e., progestins), have [[antigonadotropic]] effects,<ref name="pmid368741">{{cite journal | author = Neumann F | title = The physiological action of progesterone and the pharmacological effects of progestogens--a short review | journal = Postgraduate Medical Journal | volume = 54 | issue = Suppl 2 | pages = 11–24 | year = 1978 | pmid = 368741 }}</ref> and progestogens in sufficiently high amounts can markedly suppress the body's normal production of progestogens, androgens, and estrogens as well as inhibit [[fertility]] ([[ovulation]] in women and [[spermatogenesis]] in men).<ref name="pmid12641635" />
 
Progestogens have been found to maximally suppress circulating testosterone levels in men by up to 70 to 80% at sufficiently high doses.<ref name="WeinKavoussi2011">{{cite book| vauthors = Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA | title = Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set|url=https://books.google.com/books?id=fu3BBwAAQBAJ&pg=PA2938|date=25 August 2011|publisher=Elsevier Health Sciences|isbn=978-1-4160-6911-9|pages=2938–}}</ref><ref name="pmid519881">{{cite journal | vauthors = Kjeld JM, Puah CM, Kaufman B, Loizou S, Vlotides J, Gwee HM, Kahn F, Sood R, Joplin GF | title = Effects of norgestrel and ethinyloestradiol ingestion on serum levels of sex hormones and gonadotrophins in men | journal = Clinical Endocrinology | volume = 11 | issue = 5 | pages = 497–504 | year = 1979 | pmid = 519881 | doi = 10.1111/j.1365-2265.1979.tb03102.x| s2cid = 5836155 }}</ref> This is notably less than that achieved by [[GnRH analogue]]s, which can effectively abolish gonadal production of testosterone and suppress circulating testosterone levels by as much as 95%.<ref name="Urotext2001">{{cite book|author=Urotext|title=Urotext-Luts: Urology|url=https://books.google.com/books?id=6zjtA37qDsMC&pg=PA71|date=1 January 2001|publisher=Urotext|isbn=978-1-903737-03-3|pages=71–}}</ref> It is also less than that achieved by [[high-dose estrogen]] therapy, which can suppress testosterone levels into the castrate range similarly to GnRH analogues.<ref name="pmid7000222">{{cite journal | vauthors = Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R | title = Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial | journal = Br J Urol | volume = 52 | issue = 3 | pages = 208–15 | year = 1980 | pmid = 7000222 | doi = 10.1111/j.1464-410x.1980.tb02961.x}}</ref>